ArticleAIDS (London, England)2026
Improving cohort coverage estimation using a data triangulation framework: the Swiss HIV Cohort Study example.
Article in AIDS (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevalence, Patterns and Implications of Chemsex Substance Use Among Gay and Bisexual Men Who Have Sex With Men: A Cohort-Collaboration Between the Swiss HIV Cohort Study and the SwissPrEPared Study.Journal of the International AIDS Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo improve estimation of cohort coverage in the Swiss HIV Cohort Study (SHCS) using a data triangulation framework that compares SHCS data with multiple external data sources.
designRetrospective longitudinal analysis of the SHCS.
methodsCohort coverage of HIV diagnoses, AIDS diagnoses, and antiretroviral therapy (ART) uptake was triangulated across SHCS data (1985-2023), national HIV/AIDS surveillance (1985-2023), longitudinal antiretroviral therapy (ART) sales data (2017-2024), and a targeted literature comparison. Temporal trends in cohort coverage were assessed, and demographic representativeness was evaluated by sex, age, HIV acquisition mode, and region. Mean cohort coverage estimates were calculated for three outcomes: HIV and AIDS diagnoses (Step 1) and ART uptake (Step 2).
resultsOver 38 years, mean SHCS coverage was 62.4% for HIV diagnoses, 74.0% for AIDS, and 64.9% for ART uptake, consistent with literature-based estimates. Coverage of HIV diagnoses declined in recent years, and geographical heterogeneity was observed. The SHCS remained broadly representative across most subgroups; however, females, older adults, and people with heterosexually acquired HIV or using psychoactive substances were underrepresented, while people on single-tablet and salvage ART regimens were overrepresented.
conclusionsA data triangulation framework provides a practical approach for monitoring cohort coverage and representativeness. While the SHCS captures a broadly representative sample of diagnosed individuals, tailored strategies are needed to improve inclusion of underrepresented subgroups and maintain cohort coverage. Sustained monitoring is essential to ensure that cohort-based research remains generalizable and continues to inform clinical care and public health responses in Switzerland and beyond.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.